An important observation we made in this study was that, not only the absence of GP-BAR1 increases the susceptibility to develop an intestinal inflammation in response to a barrier braking agent, but that the expression of the receptor is robustly modulated by inflammation in rodent models of colitis and Crohn's disease patients. This evidence concerns the gene GPBAR1 and colitis.